We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medpace (MEDP) Rises As Market Takes a Dip: Key Facts
Read MoreHide Full Article
In the latest trading session, Medpace (MEDP - Free Report) closed at $622.11, marking a +1% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.17%. Elsewhere, the Dow saw a downswing of 0.26%, while the tech-heavy Nasdaq depreciated by 0.09%.
Shares of the provider of outsourced clinical development services have appreciated by 3.7% over the course of the past month, outperforming the Medical sector's loss of 0.67%, and the S&P 500's loss of 0.24%.
The investment community will be paying close attention to the earnings performance of Medpace in its upcoming release. The company is slated to reveal its earnings on October 21, 2026. In that report, analysts expect Medpace to post earnings of $4.45 per share. This would mark year-over-year growth of 15.28%. Meanwhile, the latest consensus estimate predicts the revenue to be $708.75 million, indicating a 7.4% increase compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $17.54 per share and a revenue of $2.84 billion, signifying shifts of +14.79% and +12.38%, respectively, from the last year.
It is also important to note the recent changes to analyst estimates for Medpace. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Medpace currently has a Zacks Rank of #3 (Hold).
With respect to valuation, Medpace is currently being traded at a Forward P/E ratio of 35.12. Its industry sports an average Forward P/E of 16.95, so one might conclude that Medpace is trading at a premium comparatively.
We can additionally observe that MEDP currently boasts a PEG ratio of 2.75. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical Services industry currently had an average PEG ratio of 1.59 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 99, finds itself in the top 41% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Medpace (MEDP) Rises As Market Takes a Dip: Key Facts
In the latest trading session, Medpace (MEDP - Free Report) closed at $622.11, marking a +1% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.17%. Elsewhere, the Dow saw a downswing of 0.26%, while the tech-heavy Nasdaq depreciated by 0.09%.
Shares of the provider of outsourced clinical development services have appreciated by 3.7% over the course of the past month, outperforming the Medical sector's loss of 0.67%, and the S&P 500's loss of 0.24%.
The investment community will be paying close attention to the earnings performance of Medpace in its upcoming release. The company is slated to reveal its earnings on October 21, 2026. In that report, analysts expect Medpace to post earnings of $4.45 per share. This would mark year-over-year growth of 15.28%. Meanwhile, the latest consensus estimate predicts the revenue to be $708.75 million, indicating a 7.4% increase compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $17.54 per share and a revenue of $2.84 billion, signifying shifts of +14.79% and +12.38%, respectively, from the last year.
It is also important to note the recent changes to analyst estimates for Medpace. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Medpace currently has a Zacks Rank of #3 (Hold).
With respect to valuation, Medpace is currently being traded at a Forward P/E ratio of 35.12. Its industry sports an average Forward P/E of 16.95, so one might conclude that Medpace is trading at a premium comparatively.
We can additionally observe that MEDP currently boasts a PEG ratio of 2.75. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical Services industry currently had an average PEG ratio of 1.59 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 99, finds itself in the top 41% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.